Immunovia publ AB Cash Flow Conversion Efficiency

Latest as of June 2026: -0.870x

Immunovia publ AB cash flow conversion efficiency. Based on the latest financial reports, Immunovia publ AB (IMMNOV) has a cash flow conversion efficiency ratio of -0.870x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-20.57 Million ≈ $-2.21 Million USD) by net assets (Skr23.64 Million ≈ $2.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Immunovia publ AB (2013–2025)

Cash flow conversion efficiency of Immunovia publ AB from 2013 to 2025. This chart illustrates how Immunovia publ AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Immunovia publ AB stock quote for real-time trading data and today's change.

Immunovia publ AB Cash Flow Conversion Ratio Explained

Immunovia publ AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Immunovia publ AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Immunovia publ AB ranked by their cash flow conversion efficiency. Also see IMMNOV stock market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Octopus Renewables Infra Trust LSE:ORIT	0.039x
Intelligent Living Application Group Inc NASDAQ:ILAG	-0.142x
NFT Limited NYSE MKT:MI	-0.596x
EMMERSON PLC O.N. F:4UM	N/A
Classic Minerals Ltd AU:CLZ	0.016x
TZ Ltd AU:TZL	0.218x
Harvest Gold Corp V:HVG	-0.054x
Lakshmi Finance & Industrial Corporation Limited NSE:LFIC	-0.054x

Annual Cash Flow Conversion Efficiency for Immunovia publ AB (2013–2025)

The table below shows the annual cash flow conversion efficiency of Immunovia publ AB from 2013 to 2025. Review Immunovia publ AB (IMMNOV) financial flexibility to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr64.73 Million ≈ $6.97 Million	Skr-78.40 Million ≈ $-8.44 Million	-1.211x	+85.42%
2024-12-31	Skr11.65 Million ≈ $1.25 Million	Skr-96.75 Million ≈ $-10.41 Million	-8.306x	-278.36%
2023-12-31	Skr66.99 Million ≈ $7.21 Million	Skr-147.06 Million ≈ $-15.83 Million	-2.195x	-204.81%
2022-12-31	Skr243.80 Million ≈ $26.24 Million	Skr-175.58 Million ≈ $-18.90 Million	-0.720x	-104.71%
2021-12-31	Skr433.90 Million ≈ $46.70 Million	Skr-152.65 Million ≈ $-16.43 Million	-0.352x	-74.70%
2020-12-31	Skr599.40 Million ≈ $64.51 Million	Skr-120.70 Million ≈ $-12.99 Million	-0.201x	+21.68%
2019-12-31	Skr357.61 Million ≈ $38.48 Million	Skr-91.95 Million ≈ $-9.90 Million	-0.257x	-41.22%
2018-12-31	Skr461.95 Million ≈ $49.71 Million	Skr-84.11 Million ≈ $-9.05 Million	-0.182x	+6.91%
2017-12-31	Skr236.80 Million ≈ $25.48 Million	Skr-46.32 Million ≈ $-4.98 Million	-0.196x	-355.98%
2016-12-31	Skr276.63 Million ≈ $29.77 Million	Skr-11.87 Million ≈ $-1.28 Million	-0.043x	-26.43%
2015-12-31	Skr83.80 Million ≈ $9.02 Million	Skr-2.84 Million ≈ $-305.99K	-0.034x	+85.37%
2014-12-31	Skr35.74 Million ≈ $3.85 Million	Skr-8.29 Million ≈ $-892.20K	-0.232x	-176.53%
2013-12-31	Skr4.94 Million ≈ $531.55K	Skr-414.31K ≈ $-44.59K	-0.084x	--

About Immunovia publ AB

ST:IMMNOV Sweden Diagnostics & Research

Market Cap

$3.90 Million

Skr36.26 Million SEK

Market Cap Rank

#29007 Global

#646 in Sweden

Share Price

Skr0.05

Change (1 day)

+4.66%

52-Week Range

Skr0.04 - Skr0.34

All Time High

Skr290.00